Flunarizine Hydrochloride Capsules

(1) This product is a calcium channel blocker. It can prevent cell damage caused by pathological intracellular calcium overload due to ischemia and other reasons. This product has the following effects: (1) Relieve vasospasm, and have a lasting inhibitory effect on persistent vasospasm caused by vasoconstrictor substances, especially on the basilar artery and internal carotid artery. Its effect is 15 times stronger than that of ceramide; (2) Vestibular inhibitory effect, which can increase blood flow in the cochlear arterioles and improve vestibular organ circulation; (3) Anti-epileptic effect, this product can block pathological calcium overload of nerve cells and prevent paroxysmal depolarization and cell discharge, thereby avoiding epileptic seizures; (4) Protect the myocardium and significantly reduce ischemic myocardial damage; (5) Flunarizine also has the effect of improving renal function and can be used for chronic renal failure; in addition, this product also has anti-histamine effect.

The main component of this product is flunarizine hydrochloride. The chemical name is: (E)-1-[bis(4-fluorophenyl)methyl]-4-2(2-propenyl-3-phenyl)-piperazine dihydrochloride. Its structural formula is: Molecular formula: C26H26F2N22HCl Molecular weight: 477.42

This product is capsule

(1) Insufficient cerebral blood supply, vertebral artery ischemia, cerebral thrombosis, etc. (2) Tinnitus, dizziness. (3) Prevention of migraine. (4) Auxiliary treatment of epilepsy.

(1) For central vertigo and peripheral vertigo, including vertebrobasilar artery insufficiency, use flunarizine 10-20 mg per day, 2-8 weeks as a course of treatment. (2) For idiopathic tinnitus, use flunarizine 10 mg once a night, 10 days as a course of treatment. (3) For intermittent claudication, use flunarizine 10-20 mg per day. (4) For migraine prevention, use flunarizine 5-10 mg twice a day. (5) For cerebral arteriosclerosis and cerebral infarction recovery period, use flunarizine 5-10 mg per day.

(1) Adverse reactions of the central nervous system include: ① Drowsiness and fatigue are the most common. ② Depression may occur in long-term users, which is more common in female patients. ③ Extrapyramidal symptoms, such as involuntary movements, mandibular movement disorders, rigidity, etc. Most of them appear after 3 weeks of medication and disappear after stopping the medication. It is more likely to occur in the elderly. ④ A small number of patients may experience insomnia, anxiety and other symptoms. (2) Gastrointestinal symptoms include: burning sensation in the stomach, hyperappetite, increased food intake, and weight gain. (3) Others: A small number of patients may experience rash, dry mouth, galactorrhea, muscle aches and other symptoms. However, most of them are transient and can be relieved by stopping the medication.

This drug is contraindicated if you have a history of allergy to it or a history of depression, and it is contraindicated in patients with acute cerebral hemorrhagic disease.

Precautions for children: Since this drug can pass through the blood-brain barrier, it has clear adverse reactions in the central nervous system and the central nervous system of children is sensitive to the drug; the metabolic function is relatively weak. Although there is no detailed research data on the use of drugs in children, in principle, children should be cautious or avoid using this drug. Precautions for pregnancy and lactation: Since this drug can pass through the placental barrier and can be secreted with breast milk, although there are no reports of teratogenicity and effects on embryonic development, in principle, pregnant women and lactating women should not use this drug. Precautions for the elderly: Since the nervous system of elderly patients is more sensitive and their metabolic capacity is weaker, the dosage should be reduced as appropriate.

(1) When used in combination with alcohol, hypnotics or sedatives, the sedative effect is aggravated. (2) When used in combination with phenytoin sodium and carbamazepine, the blood concentration of flunarizine can be reduced. (3) When used in combination with cinnarizine in patients undergoing radiotherapy, it can increase the killing power of tumor cells. (4) Adding flunarizine to anti-epileptic drug treatment can improve the anti-epileptic effect.

Keep in a sealed container

10mg*30s

48 months

Heilongjiang Aolida NED Pharmaceutical Co., Ltd.

• Founded in:

  2001-12-27

• Address:

  No. 18, Economic Development Zone, Qing'an County, Suihua City, Heilongjiang Province

• Tax NO.:

  912312007336583363

• Registered Funds:

  35 million yuan

• Email:

  Log in to view